StemCell Therapy

Myriad Genetics (NASDAQ: MYGN) and Varex Imaging (NASDAQ:VREX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Myriad Genetics and Varex Imagings revenue, earnings per share (EPS) and valuation.

Varex Imaging has higher revenue, but lower earnings than Myriad Genetics.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Myriad Genetics and Varex Imaging, as provided by MarketBeat.com.

Myriad Genetics presently has a consensus target price of $20.38, suggesting a potential downside of 32.64%. Varex Imaging has a consensus target price of $33.50, suggesting a potential upside of 7.48%. Given Varex Imagings stronger consensus rating and higher probable upside, analysts plainly believe Varex Imaging is more favorable than Myriad Genetics.

Institutional & Insider Ownership

91.8% of Varex Imaging shares are owned by institutional investors. 6.2% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Myriad Genetics and Varex Imagings net margins, return on equity and return on assets.

Summary

Myriad Genetics beats Varex Imaging on 6 of the 10 factors compared between the two stocks.

Myriad Genetics Company Profile

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to enable optimal treatment, or assess a patients risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Varex Imaging Company Profile

Varex Imaging Corporation is a supplier of medical X-ray tubes and image processing solutions. The Companys segments include Medical and Industrial. The X-ray imaging system manufacturers use the Companys components for medical imaging, cargo screening and border security, to detect, diagnose and protect. The Medical business segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography, radiation therapy and computer-aided detection. The Industrial business segment designs, manufactures, sells and services products for use in security and industrial inspection applications, such as cargo screening at ports and borders and non-destructive examination in a range of applications.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

The rest is here:
Myriad Genetics (MYGN) and Varex Imaging (VREX) Financial Survey - The Ledger Gazette

This entry was posted on September 4, 2017 at 11:49 am and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |